THE GLOBAL MARKET.
In Europe and the USA, ID-NEST Medical solutions are positioned on a total market estimated at
1.2-1.4 billion €
COMPRESSIONS AND SEVERE VENOUS THROMBOSES OF THE LOWER LIMBS.
The treatment of these pathologies is not very effective using current techniques.
This mass market, with no lasting medical solution, is growing at the same rate as the population.
The market for severe venous pathologies of the lower limbs is estimated at
1.2 billion €
(Europe and USA, in 2017.).
ID Venous System may be especially effective in treating four specific indications, as a complement to the techniques currently used :
- Acute episode – May-Thurner type thrombotic patients.
- Acute episode – Patients in proximal deep vein thrombosis with obstructive risk.
- Chronic pathology – Patients with severe obstructive after effects as the result of a deep vein thrombosis.
- Chronic pathology – Symptomatic, non-thrombosed patients with May-Thurner type compression.
ID VENOUS SYSTEM PER PATHOLOGY, IN MILLION €.
MARKET SHARE AND NUMBER OF STENTS SOLD.
3,000 stents sold.
6,800 stents sold.
13,000 stents sold.
26,100 stents sold.
43,700 stents sold.
70,300 stents sold.
91,500 stents sold.
123,100 stents sold.
153,800 stents sold.
END USER TURNOVER.
Total 31 M€ in 2022
- USA 7M€
- Europe 24M€
Total 110 M€ in 2025
- USA 72M€
- Europe 38M€
Total 184 M€ in 2027
- USA 145M€
- Europe 39M€
Market data on the four biggest European markets :
TOTAL TURNOVER ARTERIAL IN MILLION €.
NUMBER OF DEVICES SOLD.
ID-NEST MARKET SHARE.